Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Chlorin E6 Gel
Chlorin E6 · 1 trial · 1 indication
Adverse events will include those that are related to study intervention.
To determine the effect of Chlorin E6 on the healing of diabetic foot ulcers, defined by a reduction in size and depth of ulcer
To determine the eradication ratio of pathogenic bacteria through the synergistic effect of local Chlorin E6-mediated Photodynamic Therapy
| Arm | Type | Description |
|---|---|---|
| Group A (IP+PDT+SOC) | EXPERIMENTAL | This group will be provided with Standard of Care treatment for DFU, along with IP application and PDT |
| Group B (SOC Only) | NO_INTERVENTION | This group will only receive the Standard of Care treatment for DFU |
| Name | Type | Description |
|---|---|---|
| Chlorin E6 Gel | COMBINATION_PRODUCT | The Group A participants in this study were received Chlorin E6 Gel-mediated Photodynamic Therapy for the management of Diabetic Foot Ulcers |
Inclusion Criteria: 1. Patients with diagnosis of Diabetes mellitus, with diabetic foot ulcer. 2. Males and females subject of age 18 years and above. 3. HbA1c of less than 12% and random blood sugars of less than 350 mg/dl. 4. Vitally stable patient with no clinical signs of sepsis, a qSOFA (quick...
Chlorin E6 is an investigational small molecule being developed for the treatment of Diabetic Foot Ulcer (DFU). It is formulated as a gel and administered as photodynamic therapy. The drug is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Chlorin E6 is a photosensitizing agent used in photodynamic therapy. When activated by light, it generates reactive oxygen species that can destroy targeted cells. In the context of diabetic foot ulcers, this mechanism is being studied to promote wound healing and reduce infection.
Chlorin E6 is being developed by United Therapeutics Corporation, a publicly traded company listed on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical trials to evaluate the safety and efficacy of Chlorin E6 Gel for the treatment of diabetic foot ulcers.
Chlorin E6 is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 3 trial is actively recruiting participants to assess the treatment's effectiveness for diabetic foot ulcers.
Chlorin E6 is being evaluated in a Phase 3 clinical trial registered as NCT07488247. This randomized, biomarker-selected study is recruiting 300 participants aged 18 years and older in Pakistan. The trial is designed to assess the safety and efficacy of Chlorin E6 Gel photodynamic therapy for diabetic foot ulcers.
Yes, Chlorin E6 is also known as Chlorin E6 Gel. The gel formulation is the specific dosage form being tested in clinical trials for the treatment of diabetic foot ulcers. Both names refer to the same investigational drug product developed by United Therapeutics Corporation.